Guilbaud, Emma http://orcid.org/0000-0001-5261-1944
Galluzzi, Lorenzo http://orcid.org/0000-0003-2257-8500
Article History
Received: 21 May 2024
Revised: 17 June 2024
Accepted: 26 June 2024
First Online: 3 July 2024
Competing interests
: LG is/has been holding research contracts with Lytix Biopharma, Promontory and Onxeo, has received consulting/advisory honoraria from Boehringer Ingelheim, AstraZeneca, OmniSEQ, Onxeo, The Longevity Labs, Inzen, Imvax, Sotio, Promontory, Noxopharm, EduCom, and the Luke Heller TECPR2 Foundation, and holds Promontory stock options. EG has no conflicts of interest to declare.